Integrating New Approach Methodologies (NAMs) into Preclinical Regulatory Evaluation of Oncology Drugs
Biomimetics · 24.11.2025 · 10 (12) · 796
DOI: 10.3390/biomimetics10120796 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Biomimetics, online erschienen am 24.11.2025. Verfasst von Maryam Sadat Mirlohi und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Mechanical Engineering, University of Victoria, Victoria, BC V8W 2Y2, Canada. Die Arbeit wurde bisher 26-mal zitiert (Crossref) und nennt 83 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Traditional animal-based preclinical models, including xenografts and genetically engineered mice, have been used for assessing pharmacodynamics, toxicity, efficacy, and safety for decades. Despite their limited ability to mimic human tumor heterogeneity, immune interactions, and microenvironmental complexity, over 90% of oncology candidates that succeed in animal studies fail in clinical trials. The New Approach Methodologies (NAMs), which include patient-derived organoids, organ-on-chip platforms, and AI-driven computational models, provide human-relevant solutions that can improve predictive validity, mechanistic insight, and ethics. Through these technologies, it will be possible to replicate tumor biology specific to patients, to support co-clinical trial designs, and to facilitate biomarker discovery while reducing animal testing. Several recent regulatory reforms, including the Food and Drug Administration (FDA) Modernization Act 2.0 and the European Medicines Agency’s NAM qualification framework, have established clear pathways for the integration of validated NAMs into preclinical drug evaluation. Critically evaluating the scientific rationale, comparative performance, and regulatory context of key NAM platforms in oncology, this review highlights opportunities for synergistic integration, technical refinement, and global harmonization in order to accelerate the development of clinically effective cancer therapeutics based on preclinical findings.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Mechanical Engineering, University of Victoria, Victoria, BC V8W 2Y2, Canada.
- Department of Clinical Biochemistry, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran 1985717413, Iran.
- Mass General Cancer Center, Department of Surgery, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02115, USA.
- Apricell Biotechnology Inc., Victoria, BC V8W 2Y2, Canada.
ORCID-Profile: Maryam Sadat Mirlohi, Amir Reza Aref
Zitieren
APA
Mirlohi, M. S., Yousefi, T., Aref, A. R., & Seyfoori, A. (2025). Integrating New Approach Methodologies (NAMs) into Preclinical Regulatory Evaluation of Oncology Drugs. Biomimetics, 10(12), 796. https://doi.org/10.3390/biomimetics10120796
Vancouver
Mirlohi MS, Yousefi T, Aref AR, Seyfoori A. Integrating New Approach Methodologies (NAMs) into Preclinical Regulatory Evaluation of Oncology Drugs. Biomimetics. 2025;10(12):796. doi:10.3390/biomimetics10120796
BibTeX
@article{Mirlohi2025,
author = {Mirlohi, Maryam Sadat and Yousefi, Tooba and Aref, Amir Reza and Seyfoori, Amir},
title = {Integrating New Approach Methodologies (NAMs) into Preclinical Regulatory Evaluation of Oncology Drugs},
journal = {Biomimetics},
year = {2025},
volume = {10},
number = {12},
pages = {796},
doi = {10.3390/biomimetics10120796}
}
EUVIMED